Latest Institutional Placement News

Comet Ridge has completed a $40.9 million capital raise combining a Share Purchase Plan and a two-tranche placement to fund full acquisition and development of its Mahalo Gas Project.

G50 Corp has raised A$26.25 million through a well-supported institutional placement, with Hancock Prospecting taking a significant stake. The funds will accelerate drilling and metallurgical work at its Golconda and White Caps projects in the United States.

DXN Limited has landed a $1.2 million contract for a key Pacific submarine cable project while advancing its maiden AI HPC modular data centre deal and expanding manufacturing in Southeast Asia.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.

Beetaloo Energy has pushed construction of its Carpentaria Gas Plant forward, maintaining schedule and budget for Q4 2026 commissioning, while its Carpentaria-5H well delivers steady gas flow with low decline rates.

Barton Gold’s June quarter report highlights exceptional high-grade gold and silver assay results across its South Australian projects, backed by a $26 million institutional placement that strengthens its cash position and development outlook.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.

Elevra Lithium’s North American Lithium operation hit a new monthly spodumene concentrate production record in May 2026 while closing a US$298 million financing package to fund expansion and project development.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.

Breakthrough Minerals has delivered promising assay results from its maiden drilling at Barbara, underpinning resource growth potential, while launching a new drilling campaign at Hazel Creek and securing A$5.15 million to fund an expanded exploration push.